anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A water-soluble blood coagulating enzyme is prepared by treating a lipoid obtained from lungs, brains or soya beans with pancreatin or trypsin in the presence of a solvent, which is subsequently removed under reduced pressure.  Cow lungs and sheeps&#39; brains are preferred sources of lung and brain lipoids. The examples are concerned with preparations formed from (a) an acetone precipitated fraction of trypsin and an etherial solution of sheeps&#39; brains; (b) pancreation and an etherial solution of sheeps&#39; brains; (c) crystallized trypsin and a benzene solution of soya bean lipoids.ALSO:A water soluble blood coagulating preparation is prepared by treating a lipoid obtained from lungs, brains or soya beans with pancreatin or trypsin in the presence of a solvent, which is subsequently removed under reduced pressure.  Cow lungs and sheeps&#39; brains are preferred sources of lung and brain lipoids. The examples are concerned with preparations formed from (a) an acetone precipitated fraction of trypin and an etherial solution of sheeps&#39; grains; (b) pancreatin and an etherial solution of sheeps&#39; brains; (c) crystallized trypsin and a benzene solution of soya bean lipoids.  The sterile material is stored in an atmosphere of nitrogen.
PURPOSE: To obtain an enhancer for the bactericidal efficacy, containing capric acid and/or d-dodecalactone in a quaternary ammonium-based bactericide and capable of enhancing the bactericidal efficacy of the bactericide. CONSTITUTION: This enhancer contains capric acid and/or d-dodecalactone as active ingredients in a small amount of &lt;=0.0005vol./wt.% in a quaternary ammonium-based bactericide. (e.g. cetylpyridinium chloride). The bactericidal efficacy of a medicinal composition for the oral cavity containing the quaternary ammonium-based bactericide blended therein can be enhanced by blending the capric acid and/or d-dodecalactone as the active ingredients therein. The composition is especially effective in contact with bacteria of Streptococcus mutans, Prevotel 1a intermedia, Haemophilus actinomycetemcomitans and Fusobacterium nucleatum. The enhancer is capable of preventing diseases in the oral cavity such as periodontitis, gingivitis or carious teeth and is useful for cleaning especially a gingival marginal part and preventing halitosis.
The invention concerns inventive nanoparticles (NPs), their compositions and their use as therapeutic agents in particular in the field of oncology and/or as imaging agents. The NPs are composed of first nanoparticles of at least one high-Z metal oxide material, to which smaller second nanoparticles are covalently bonded at the first nanoparticles&#39; surface. The second nanoparticles are composed of either a) at least one noble metal or at least one metal oxide, metal sulfide, metal selenide or metal sulfide/selenide that is a Fenton or Fenton-like reaction catalyst. The inventive NPs generate a surprisingly therapeutic effect when exposed to ionizing radiation such as X-Rays, γ-Rays, protons, neutrons, radioactive isotopes and/or electron beams. Thus, the NPs may be used as radioenhancers in the field of oncology. The nanoparticles may also be used as contrast agents.
PROBLEM TO BE SOLVED: To obtain the subject compound having strong affinity to D4 receptor and not having adverse effect such as extrapyramidal disorder or granulocytopenia and useful as a treating medicine for schizophrenia, etc. SOLUTION: This compound is represented by formula I [A&lt;1&gt; is an amino, a lower alkyl, etc.; A&lt;2&gt; is H, a lower alkyl, etc.; X is a halogen ; W&lt;1&gt; and W&lt;2&gt; are each a lower alkyl, an aryl, etc.; (m) and (n) are each 0-2], e.g. 6-(1-benzyl-4- piperidinyl)amino-4-chloro-2-methyl-5-(4-chlorophenylthio)pyrimidine. The pyrimidine derivative of formula I is produced by reacting malonate with amidine in the presence of a base in an inert solvent such as ethanol at room temperature to 80 deg.C to afford a compound of formula II, reacting the compound of formula II with a brominating agent such as Br to provide a compound of formula III, reacting the resultant compound with thiol in the presence of a base in an inert solvent at room temperature to 150 deg.C to afford a compound of formula IV, reacting the resultant compound with a halogenating agent at a temp. of 0-120 deg.C to afford a compound of formula V, reacting the compound of formula V in the presence of an amine at a temp. of 0-85 deg.C.
PURPOSE: To detect hydrogen peroxide, hydrogen peroxide forming system, peroxidase or peroxidative effect substance by using as color forming agent specific aniline derivative, acid or base and its salt together with oxidizable coupling component in a Trinder reaction. CONSTITUTION: The aniline derivative is represented by a formula. In the formula, R1 is hydrogen lower alkyl, R2 is hydrogen, lower alkyl group, R3 is hydrogen, carboxy, R4 and R4 &#39; are hydrogen, halogen, R5 is hydrogen, lower alkyl group, R6 is hydroxy, lower alkoxy group. The compound is stable substance, and the substance itself is excellent water soluble or reacted with conventional acid or base to become easy soluble in salt. As the oxidizable coupling component, 4-amonoantipyrine, 2-hydrazo 1-2 are advantageous. Specific aniline derivative, acid or base and its salt and the coupling agent adopt known activator if it is used for detecting H2 O2 , H2 O2 generating system, peroxidase, peroxidative effect substance, and the Trinder reaction is rapid in the degree not requiring for additional activation.
NEW MATERIAL:A compound of formulaI(A is CH3S-CH2-CH&lt;). EXAMPLE:Boc-L-Tyr-GlY-GlY-L-Phe-L-Leu-al. USE:A drug that can be expected as an analgesic or its synthetic intermediate. It has a strong analgesic activity. PREPARATION:A peptide alcohol of formula II is made to react with a sulfur trioxide complex in DMSO in the presence of triethylamine to give the compound of formulaI. The amounts of triethylamine and sulfur tiroxide used in the above reaction is sufficiently 2.5 equivalents, however, about 3 equivalents respectively. Examples of sulfur trioxide complexe are derived from sulfur trioxide and pyridine, dioxane or DMF. In the formula, Boc represents tertiary butyl carbonyl; Tyr, the residue of tyrosine; Gly, the residue of glycine and Phe, the residue of phenylalanine.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for efficiently producing a Japanese refined Sake enzyme-treated product useful for food, cosmetics, etc. and high in storage stability.  &lt;P&gt;SOLUTION: The method for producing the Japanese refined Sake enzyme-treated product is provided, including removing ethanol from Japanese refined Sake followed by conducting a treatment with a glucose oxidase. In the treatment, the ethanol concentration of the resultant Japanese Sake concentrate is lower than 1 mass%, and the content of α-ethyl glucoside is 0.3 mass% or higher. After conducting the above treatment, the method also includes a treatment of removing gluconic acid transformed from the glucose.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Therapeutic compounds and compositions for the treatment of infectious diseases are disclosed. The compounds are xanthones and xanthone derivatives, such as 3,5-bis-ε-(N,N-diethylamino)amyloxyxanthone. The described compositions include such compounds and a pharmaceutical carrier. These compositions also can include additional materials conventionally used to form therapeutic compositions. 3,5-bis-ε-(N,N-diethylamino)amyloxyxanthone has an IC50 for Plasmodium falciparum of about 0.15 νM, and an IC50 for Leishmania mexicana of &lt; &lt;0.5 νM. These compositions are additionally useful for forming soluble complexes with heme and porphyrins.
Small, anti-inflammatory compounds that are peptide analogs are described useful to inhibit inflammation of a mammal&#39;s skin, mucous membranes, or lacerations of the musculature or injury to the brain or leakage of fluids into the air spaces of the lungs. Peptide analogs of the invention have the primary sequence TN-A1-A2-A3-A4-A5-A6-Tc where one of the moieties is in the D-configuration. A1 and A2 are each a basic polar amino acid while each of A3, A4, and A6 is a hydrophobic amino acid. A5 can be a variety of structures and appears to function to optimize the spatial relationship between the hydrophobic and the basic residues. TN is selected or modified to convey resistance against enzymatic degradation. Tc is an amino group or an amidated amino acid, preferably hydrophobic.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide magnetic gel particles which are gel particles producible under mild conditions, resultantly preventing even deterioration of a physiologically active substance, aggregating and localizing the gel particles in a diseased site by magnetic force applied from the outside of a body or a device inserted into the body and efficiently treating affected parts.  &lt;P&gt;SOLUTION: The method for production is carried out as follows. (A) An aqueous solution containing an iron(II) salt, (B) an aqueous solution containing a basic substance and (C) an aqueous solution containing ascorbic acid are suspended and mixed into a lipophilic liquid. (D) A polymer modified with a xanthene dye and (E) an aqueous solution containing the physiologically active substance are suspended and mixed with the resultant suspension. Dispersed particles are then photo-cross-linked by irradiating the mixture liquid with visible light to produce the magnetic gel particles.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for treatment of an inflammatory disorder of a test subject, especially; and to provide a method for treatment of arthritis.  &lt;P&gt;SOLUTION: A composition is for the treatment of the test subject affected by the arthritis. The composition contains a function blocking antibody or a fragment of the antibody in an amount effective for lowering an arthritis score by about 65% or more compared with a test subject treated with a control antibody. The function blocking antibody or the fragment of the antibody is capable of being bound to an epitope of VLA-1 which is a composition containing amino acid residues 92-97 shown in Fig. 15.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition has antibody raised to interkeukin-6 receptors and can be used for preparing preparations for treatment of patients with diseases caused by blood state damage, immunological disturbances, tumors and other diseases caused by formation of IL-6. In part, composition can be used for prophylaxis and treatment of patients with plasmacytosis, hyperimmunoglobulinemia, anemia, nephritis, cachexia, rheumatism, Kastlman&#39;s disease, mesangial proliferating nephritis. Monoclonal antibody, antibody PM-1, chimeric antibody, human antibody, modified human antibody PM-1 can be used as an antibody. Composition shows effectiveness against multitude of diseases caused by formation of IL-6 but it does not shows any effect at normal level of IL-6. EFFECT: enhanced effectiveness of composition. 14 cl, 18 dwg, 4 tbl, 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a process for treating an oil derived from microorganisms.  &lt;P&gt;SOLUTION: This process for treating an oil comprises bringing the oil into contact with a polar solvent to extract at least one compound that is soluble in the solvent, and then separating the solvent containing the compound from the so treated oil. The oil is microbially derived, and extracted either from a fermentation broth or a filtrate thereof using hexane. The compound to be extracted is usually a sterol or a diglyceride. The solvent is ethanol having up to 5% water. The oil can contain a polyunsaturated fatty acid such as 18C, 20C or 22C ω-3 or ω-6 fatty acid, such as arachidonic acid.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To improve bioactivity and peeling strength and to prevent the failure with lapse of time under a condition under which a thermal change arises by improving the matching of the coefft. of thermal expansion of a metallic base body and ceramics and improving joining strength. CONSTITUTION:The ceramics of the bioimplant formed by laminating ceramics on a metallic base body is formed of a bioactive ceramic material having a non-calcium phosphate type compsn. consisting essentially of at least one kind of the metal oxide selected from the group consisting of an alkaline earth metal oxide and alkaline metal oxide and SiO2. The coefft. of thermal expansion alpha1 of the ceramics and the coefft. of thermal expansion alpha&#39; of the base bod material are specified to a 0.5alpha&#39;&lt;=alpha1&lt;=1.5alpha&#39; range. An intermediate layer is provided between the base body and the ceramics and the coefft. of thermal expansion is changed stepwise.
In a new pharmaceutical combination, the herb,  Vitex agnus - castus  (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens&#39; fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a peptide which prevents and treats viral and bacterial infection in livestock including poultry by activating their immune systems and to provide a feed containing the same.  &lt;P&gt;SOLUTION: The immunity-activating peptide is a peptide obtained by subjecting the blood of livestock to treatment with subcritical water or treatment with a protease. The peptide is especially desirably one prepared by treating the blood prepared by removing fibrin from blood in advance. And, the feed is a feed containing the immunity-activating peptide. The peptide and the feed can activate the immune systems of livestock, so that they can prevent and treat diseases caused by various viruses or bacteria.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain a polysaccharide effective in the treatment of hepatitis B by immersing fibers of a gramineous plant in a culture medium having a specific composition to thereby ferment them. CONSTITUTION:The title polysaccharide is a soluble one obtained by immersing fibers of a gramineous plant in a culture medium containing ammoniacal nitrogen, nitrate nitrogen, a soluble phosphate, and a soluble potassium salt to thereby ferment the fibers. This polysaccharide contains a secondary amine component, and the main component of the polymer has a mol.wt. in terms of dextran of 70X10&lt;3&gt; or higher. A preferred example of the culture medium contains 0.01-0.5wt.% culture medium base containing 1.0wt.% ammoniacal nitrogen, 5.5wt.% nitrate nitrogen, 6.0wt.% soluble phosphate, and 19.0wt.% soluble potassium salt. When this fermentation is conducted while irradiating the fibers with sunlight, rotting caused by germs adherent to the fibers can be prevented.
PURPOSE:To obtain a hypotensor having excellent potassium channel activation activity by using a specific thiazolo[5,4-b]azepine derivative as an active component. CONSTITUTION:The objective agent contains, as an active component, a compound of formula I (R&lt;1&gt; is H, aliphatic group, carboxylic acid acyl or sulfonic acid acyl each of which may have substituents; R&lt;2&gt; is H, aromatic group or aliphatic group each of which may have substituents) or its salt, e.g. 2-(4- chlorostyryl)-5,6,7,8-tetrahydro-4H-thiazolo[5,4-b]azepine. The compound is useful as a remedy for circulatory diseases of mammals such as hypertension or stenocardia. It is administered twice or thrice a day for adult preferably at a rate of 0.5-20mg per dose in the case of oral administration or 0.3-10mg per dose in the case of parenteral administration. The compound of formula I can be produced by reacting a compound of formula II with a reactive derivative of carboxylic acid of formula R&lt;2&gt;COX and treating the resultant compound of formula III with a sulfurizing agent.
The present invention discloses a wattle-necked soft-shell turtle hemorrhage preventing and treating feed and a preparation method thereof, which belongs to the technical field of turtle feed processing. The feed includes the following raw materials: ampullaria gigas spix, livestock and poultry leftover, earthworms, grasshoppers, pumpkins, sweet potatoes, corn, dimethyl-beta-propiothetin, betaine, sodium diacetate, disodium 5&#39;-guanylate, edible salt and Chinese herbal medicine preparations. The feed is produced by drying, crushing, screening, mixing, granulating, drying, cooling, packaging and other steps. The wattle-necked soft-shell turtle hemorrhage preventing and treating feed of the present invention combines the effects of various Chinese herbal medicines and can play roles in cooling blood and preventing bleeding, reducing inflammation and promoting tissue regeneration, clearing heat and internal heat, etc. The wattle-necked soft-shell turtles have good absorption effects and long duration of the Chinese herbal medicine preparations, and the feed can enhance the disease resistance of the wattle-necked soft-shell turtles, effectively reduce the probability of wattle-necked soft-shell turtle suffering from hemorrhage, reduce the risk of cultivation, and improve the economic efficiency of raising households. The wattle-necked soft-shell turtle hemorrhage preventing and treating feed has reasonable preparation and strong palatability, and can increase intake, improve growth rate and shorten growth cycle of wattle-necked soft-shell turtles.
FIELD: medicine, orthopedics, neurology. SUBSTANCE: before operation one should conduct electroneuromyographic testing and at detecting the signs of nervous squeezing and ischemia for 14-21 d it is necessary to perform stimulating therapy. For this purpose, one should intramuscularly inject 0.1%-ubretide solution in a day, alternate every other day subcutaneous injection of 5%-vitamin B6 solution and 3%-vitamin B1 solution and perorally it is necessary to introduce dibasol 3-4 times daily. In postoperative period, for 3-5 d, beginning immediately after the end of anesthesia it is necessary to carry out local hypothermy at cooling agent&#39;s temperature being 5-7 C per 40-60 min, every other 2.5-3 h. On the second day after operation at the background of continuous stimulating therapy one should introduce 0.05%-proserine solution through microcatheter applied towards affected nerve during operation at the dosage being 2 times lower against age one and 10-30 units of lidase once daily. The method in question enables to shorten therapy terms and decrease the risk in developing postoperative complications. EFFECT: higher efficiency of therapy. 1 ex
A composition for inhibiting lipofuscin accumulation or removing lipofuscin is disclosed. A  Chryseobacterium  sp. strain, a lysate of the  Chryseobacterium  sp. strain, a culture of the  Chryseobacterium  sp. strain, or an extract of the lysate or culture is included in the composition. The composition provides an anti-aging effect by inhibiting lipofuscin accumulation or removing lipofuscin. The composition also provides an effect of preventing, ameliorating or treating the diseases caused by the lipofuscin accumulation, such as skin hyperpigmentation, Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, myocardial infarction and age-related macular degeneration.
NEW MATERIAL:A compound (salt) expressed by formula I [X is CH2Z (Z is H, alkyl, hydroxy, halogen, acyloxy, alkoxy, etc.) or the formula C(R&lt;3&gt;)2OH (R&lt;3&gt; is alkyl); Y is hydroxy; X and Y together represent O=, OCH2, CO, etc.]. USE:A preventing and treating agent for diseases, inflammation, allergy, tumor, etc., of cardiovascular systems having C-kinase inhibitory action. PREPARATION:For example, a solution of K-252 expressed by formula II (RA is methyl, etc.; RB is H) in anhydrous tetrahydrofuran is cooled with ice and lithium aluminum hydride is added to stir the reaction mixture at room temperature for 2hr. Methanol is then added to decompose the excess reducing agent and the reaction mixture is filtered through celite to give a filtrate, which is washed with 1N hydrochloric acid and saturated aqueous saline solution and dried with anhydrous sodium sulfate. The solvent is removed under reduced pressure to give a residue, which is then purified by gel chromatography to afford the aimed compound expressed by formula I.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide food and drink useful for promoting fat combustion, enhancing basal metabolism and improving obesity, when ingested.  &lt;P&gt;SOLUTION: The food and drink contain hydroxycitric acid or its salt, and carnitine or its salt, and/or a precursor thereof. The precursor of the cartinine contained in the food and drink comprises any one of lysine or its salt and methionine, or both of the lysine or its salt and the methionine. The food and drink further contain coenzyme Q10. Thus, the food and drink are useful for promoting the fat combustion, and/or enhancing the basal metabolism and/or improving the obesity.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
1,219,345. Plant extracts. FARBWERKE HOECHST A.G. 4 June, 1968 [3 June, 1967], No. 26464/68. Heading A5B. A pharmacologically active substance is isolated from Ravensara aromatica (also known as Laurus aromatica and Agatophyllum ravensara) by extracting the bark thereof with a lower alcohol containing 1 to 3 carbon atoms, e.g. methanol or ethanol, to extract a substance which is soluble in the lower alcohol and, isolating the active substance from the extract and, if, desired, treating the product obtained, which is a hydrochloride, with a base to give the free base. The active substance may be isolated from the extract by evaporating the extract to dryness, purifying the solid residue by chromatography, e.g. using aluminium oxide or silica gel as absorbent and an organic solvent system containing from 2 to 30% by volume of a lower alcohol as eluent, and isolating the active substance from the eluate. Undesired accompanying substances may be removed from the bark by extraction with petroleum ether, chloroform or carbon tetrachloride before the active substance is extracted. The extracted active substance in the free base form has a mpt of 223-224C. contains C 62.7%, H 6.5%, N 4.1%, O 26.7% has a mol. wt. of about 355 (by mass spectrometry), U.V. (in methanol) maxima at 270 (1g# 1 =4.622) and 300 mÁ, (lg# 2 =4.249), a specific rotation of [α]&lt;SP&gt;D&lt;/SP&gt; 20 =+172 (in ethanol) and an 1.R. spectrum in KBr as shown in the attached chart. Pharmacological preparations having blood pressure lowering activity comprise the extract in the form of a free base or a physiologically tolerable salt thereof in admixture or conjunction with a pharmaceutically acceptable carrier. The preparation may be administered orally or intravenously in the form of tablets, dragees or aqueous solutions.